Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab for maintenance of response in Crohn's disease (ENACT-2)
NCT00032786Phase 3Completed
- Sponsor
- Biogen
- Start
- Mar 2002
- Primary completion
- Mar 2004
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Natalizumab 300 mg IV every 4 weeks with Placebo IV every 4 weeks (2 arms). Primary endpoint: Maintenance of clinical response through week 60. Started Mar 2002; status: completed.
02
Drugs
natalizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00032786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00032786.